News Category
Onco-Innovations has signed a non-binding LOI with Ifowonco Informatics to potentially gain exclusive rights to a small-molecule LAG-3 inhibitor progr...
Creative Biolabs has expanded its complement assay services, offering customizable solutions like C3b deposition and hemolytic inhibition assays, to s...
Quantum BioPharma's Lucid-MS offers a novel approach to multiple sclerosis by targeting myelin degradation, potentially addressing disability progress...
Silo Pharma's receipt of a Canadian patent allowance for SPC-15 strengthens its global IP position and advances its mission to bring an intranasal PTS...
Quantum BioPharma's Lucid-MS, a novel myelin-protecting therapy for multiple sclerosis, has received FDA clearance for phase 2 trials, marking a shift...
Regentis Biomaterials' recent Japanese patent allowance and U.S. patent issuance bolster its manufacturing and IP foundation for GelrinC, a key step a...
VERAXA Biotech's collaboration with Ardigen uses AI to optimize dual-target combinations for cancer therapies, potentially reducing development risks ...
VERAXA Biotech's collaboration with Ardigen to integrate AI into its BiTAC platform could improve target validation, reduce development risks, and unl...
The American Heart Association is accepting applications for its 2026 Health Tech Competition to bridge the gap between promising health technologies ...
Scientists have identified a protein on glioblastoma cells that could be targeted to make the cancer more susceptible to existing treatments, offering...
NanoViricides has received regulatory approval to start a Phase II trial of its oral antiviral NV-387 for Ebola in the DRC, potentially offering a mor...
Helus Pharma appoints Regina Donohue as Chief People Officer and Dr. Suresh Durgam to its Scientific Advisory Board, signaling strategic preparation f...
The 20th Annual Sickle Cell Disease Educational Summit, hosted by Cayenne Wellness Center, will convene in Long Beach and online from September 16-20,...
Helix BioPharma's appointment of Dr. Markus Loeffler as CMO signals a strategic push to execute its clinical development plans, particularly the Phase...
Quantum BioPharma reports significant expense reductions and FDA approval for its Phase 2 trial of Lucid-MS, a potential treatment for progressive mul...
Regentis Biomaterials is simultaneously advancing its GelrinC cartilage repair device through U.S. pivotal trials and European commercialization, aimi...
Alpha Cognition's Q2 revenue jumped 71% quarter-over-quarter to $6.0M, driven by strong underlying demand for ZUNVEYL, despite limited payer adoption,...
The Lung Cancer Foundation of America and the International Association for the Study of Lung Cancer have awarded $200,000 each to two early career re...
PX1 Research's announcement of 99%+ purity peptides through seven-stage testing underscores a shift toward pharmaceutical-grade quality standards in t...
A new review in World Journal of Pediatric Surgery synthesizes operative strategies and emerging tools for necrotizing enterocolitis, emphasizing bowe...
Onco-Innovations is building the scientific and manufacturing foundation for its precision oncology candidate ONC010, aiming to advance toward first-i...
Regentis Biomaterials' GelrinC hydrogel implant, backed by recent EU approval for a more efficient manufacturing process and progress in U.S. trials, ...
New research from the University of Manchester identifies a little-known group of immune cells as essential for initiating and sustaining the body's a...
Quantum BioPharma reported reduced Q2 expenses and FDA approval to initiate a Phase 2 trial for Lucid-MS in progressive multiple sclerosis, strengthen...
Regentis Biomaterials is advancing its cartilage repair product GelrinC through parallel US clinical and European commercial tracks, with Phase III en...
Lantern Pharma reported Q2 2026 results highlighting clinical progress, FDA and EMA interactions, and the spin-off of Open Medicine AI, while reducing...
Helus Pharma reports progress in its Phase 3 pivotal trials for HLP003 in major depressive disorder, with topline data expected in Q4 2026, and advanc...
DM Clinical Research marks its 20th anniversary, highlighting its growth into a leading network with over 35 sites and 35,000 patients enrolled, under...
NeOnc's NEO100 meets primary endpoint in Phase 2a for recurrent brain cancer, showing promising survival data and setting the stage for FDA alignment,...
PX1 Research expands its dual-incretin peptide catalog with domestically manufactured Retatrutide and Tirzepatide, verified via HPLC batch testing to ...
Quantum BioPharma's Lucid-MS candidate aims to address progression independent of relapse activity, a key driver of long-term disability in MS, markin...
As the Bundibugyo Ebola outbreak in the DRC escalates, GeoVax highlights its MVA-based vaccine candidates and expertise, positioning itself for potent...
Drugmakers are investing approximately $500 billion in the U.S. to avoid tariffs, which could reshape pharmaceutical manufacturing and pricing.
Nutriband's CEO will showcase its AVERSA abuse-deterrent technology at the 2026 Georgia Life Sciences Summit, underscoring the company's role in addre...
Quantum BioPharma's FDA approval to move its multiple sclerosis candidate Lucid-MS into Phase 2 trials marks a significant step toward a neuroprotecti...
PX1 Research launches a line of US-manufactured sublingual peptide strips, including Retatrutide, Tirzepatide, and BPC-157, offering a needle-free alt...
PX1 Research's adoption of cGMP quality control and seven-stage HPLC purity verification for all US-manufactured research peptides establishes a new b...
NanoViricides' regulatory approval to trial its oral antiviral NV-387 for Ebola in the DRC may offer a more accessible treatment option in outbreak se...
New research from the University of Virginia suggests focused ultrasound could make brain cancer treatments more effective and less harmful, potential...
Peer-reviewed preclinical data show Telomir-Zn suppresses tumor growth in TNBC models, supporting its advancement to a Phase 1/2 clinical trial.
Quantum BioPharma's FDA approval to initiate Phase 2 trials for Lucid-MS, a neuroprotective candidate targeting demyelination, marks a significant ste...
Tonix Pharmaceuticals' Q2 2026 revenue surged to $13.5 million, propelled by TONMYA's market uptake, signaling a significant commercial milestone for ...
Tonix Pharmaceuticals' Q2 2026 revenue surged to $13.5 million, led by TONMYA sales, signaling commercial success and pipeline progress.
Tonix Pharmaceuticals' Q2 2026 revenue surged to $13.5 million, led by $11 million in TONMYA sales, signaling strong market adoption and a promising o...
A new narrative review provides a comprehensive framework for risk-adapted diagnosis and treatment of childhood neuroblastoma, emphasizing the importa...
Regentis Biomaterials is progressing its GelrinC cartilage regeneration technology through clinical trials, regulatory submissions, and commercializat...
Quantum BioPharma is progressing its two-pronged approach targeting neurological health through its MS therapy Lucid-MS and alcohol metabolism supplem...
Quantum BioPharma is progressing its two-pronged approach to neurological health, with Lucid-MS for multiple sclerosis and unbuzzd for alcohol metabol...
